5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Status:
Not yet recruiting
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
In this study, we aim to investigate the efficacy and safety of 5 years of adjuvant imatinib
treatment in patients with tumor rupture defined by Nishida classification or those with a
tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.